Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs

被引:34
|
作者
Hoj, Stine Bordier [1 ]
Jacka, Brendan [1 ]
Minoyan, Nanor [1 ,2 ]
Artenie, Andreea Adelina [1 ,2 ]
Bruneau, Julie [1 ,3 ]
机构
[1] CRCHUM, 900 Rue St Denis,Local R05-746, Montreal, PQ H2X 0A9, Canada
[2] Univ Montreal, Ecole Sante Publ, 7101 Ave Parc, Montreal, PQ H3N 1X9, Canada
[3] Univ Montreal, Fac Med, Dept Med Familiale & Med Urgence, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada
基金
加拿大健康研究院;
关键词
Hepatitis C virus; Treatment; Health services; Injection drug use; Theoretical framework; Ecological framework; HEPATITIS-C VIRUS; PATIENT-REPORTED OUTCOMES; LONG-TERM CONDITIONS; HEALTH-CARE; HIV CARE; UNDERSTANDING BARRIERS; TREATMENT CANDIDACY; BEHAVIORAL-MODEL; UNITED-STATES; SPECIALIST ASSESSMENT;
D O I
10.1016/j.drugpo.2019.04.001
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
As direct-acting antiviral (DAA) therapy costs fall and eligibility criteria are relaxed, people who inject drugs (PWID) will increasingly become eligible for HCV treatment. Yet eligibility does not necessarily equate to access. Amidst efforts to expand treatment uptake in this population, we seek to synthesise and clarify the conceptual underpinnings of access to health care for PWID, with a view to informing research and practice. Integrating dominant frameworks of health service utilisation, care seeking processes, and ecological perspectives on health promotion, we present a comprehensive theoretical framework to understand, investigate and intervene upon barriers and facilitators to HCV care for PWID. Built upon the concept of Candidacy, the framework describes access to care as a continually negotiated product of the alignment between individuals, health professionals, and health systems. Individuals must identify themselves as candidates for services and then work to stake this claim; health professionals serve as gatekeepers, adjudicating asserted candidacies within the context of localised operating conditions; and repeated interactions build experiential knowledge and patient-practitioner relationships, influencing identification and assertion of candidacy over time. These processes occur within a complex social ecology of interdependent individual, service, system, and policy factors, on which other established theories provide guidance. There is a pressing need for a deliberate and nuanced theory of health care access to complement efforts to document the HCV 'cascade of care' among PWID. We offer this framework as an organising device for observational research, intervention, and implementation science to expand access to HCV care in this vulnerable population. Using practical examples from the HCV literature, we demonstrate its utility for specifying research questions and intervention targets across multiple levels of influence; describing and testing plausible effect mechanisms; and identifying potential threats to validity or barrierS to research translation.
引用
收藏
页码:11 / 23
页数:13
相关论文
共 50 条
  • [1] HCV direct-acting antiviral therapy adherence in people who inject drugs
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2024, 21 : 141 - 141
  • [2] HCV direct-acting antiviral therapy adherence in people who inject drugs
    Hindson, Jordan
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2024, 21 (03) : 141 - 141
  • [3] Direct-acting antiviral agents for HCV infection affecting people who inject drugs
    Jason Grebely
    Behzad Hajarizadeh
    Gregory J. Dore
    Nature Reviews Gastroenterology & Hepatology, 2017, 14 : 641 - 651
  • [4] Direct-acting antiviral agents for HCV infection affecting people who inject drugs
    Grebely, Jason
    Hajarizadeh, Behzad
    Dore, Gregory J.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (11) : 641 - 651
  • [5] Uptake of HCV treatment among people who inject drugs in the direct-acting antiviral era in a Canadian setting
    Socias, M. E.
    Ti, L.
    Wood, E.
    Nosova, E.
    Hull, M.
    Hayashi, K.
    Debeck, K.
    Milloy, M-J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 383 - 383
  • [6] Integrating hepatitis C and addiction care for people who inject drugs in the era of direct-acting antiviral therapy
    Bird, Kathleen
    Socias, Maria Eugenia
    Ti, Lianping
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2018, 59 : 1 - 2
  • [7] Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era
    Valerio, Heather
    McAuley, Andrew
    Innes, Hamish
    Palmateer, Norah
    Goldberg, David J.
    Munro, Alison
    Taylor, Avril
    Hutchinson, Sharon J.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2018, 52 : 115 - 122
  • [8] Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era
    Falade-Nwulia, Oluwaseun
    Gicquelais, Rachel E.
    Astemborski, Jacquie
    McCormick, Sean D.
    Kirk, Greg
    Sulkowski, Mark
    Thomas, David L.
    Mehta, Shruti H.
    LIVER INTERNATIONAL, 2020, 40 (10) : 2407 - 2416
  • [9] Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C
    Dore, Gregory J.
    Valerio, Heather
    Grebely, Jason
    LIVER INTERNATIONAL, 2020, 40 (10) : 2353 - 2355
  • [10] HCV REINFECTION AFTER SUCCESSFUL TREATMENT WITH DIRECT-ACTING ANTIVIRAL THERAPY (DAA) IN PEOPLE WHO INJECT DRUGS (PWID)
    Patsi, Marina
    Koustenis, Kanellos-Rafail
    Kranidioti, Hariklia
    Fylaktos, Panagiotis
    Vasileiadi, Sofia
    Antonakaki, Pinelopi
    Koutli, Evangelia
    Deutsch, Melanie
    Anagnostou, Olga
    Manolakopoulos, Spilios
    GASTROENTEROLOGY, 2021, 160 (06) : S825 - S825